Table 1.
Clinical and laboratory parameters at the time of rituximab therapy in the study group as a whole and in patients who achieved or did not achieve stable remission of proteinuria considered separately
| All Patients (n = 50) | Patients with Remission (n = 10) | Patients without Remission (n = 40) | |
|---|---|---|---|
| Demographics | |||
| age (yr) | 53.2 ± 16.5 | 46.6 ± 20.1 | 54.9 ± 15.3 |
| male gender | 31 (62%) | 1 (10%) | 30 (75%)d |
| Clinical parameters | |||
| body weight (kg) | 74.0 ± 18.2 | 60.3 ± 28.7 | 77.8 ± 12.0b |
| systolic BP (mmHg) | 133.9 ± 17.7 | 127.0 ± 11.9 | 135.6 ± 18.6 |
| diastolic BP (mmHg) | 81.5 ± 11.7 | 78.3 ± 7.5 | 82.3 ± 12.5 |
| mean BP (mmHg) | 98.6 ± 12.4 | 94.6 ± 8.3 | 99.6 ± 13.2 |
| Laboratory parameters | |||
| Hb concentration (g/dl) | 12.7 ± 1.8 | 11.4 ± 1.2 | 13.0 ± 1.8a |
| hematocrit (%) | 37.1 ± 5.9 | 34.4 ± 3.2 | 37.9 ± 6.3a |
| cholesterol (mg/dl) | 277.5 ± 65.7 | 273.1 ± 71.3 | 278.6 ± 65.1 |
| triglycerides (mg/dl) | 175.1 ± 81.0 | 112.5 ± 56.3 | 192.4 ± 78.7b |
| serum creatinine (mg/dl) | 1.4 ± 0.6 | 1.0 ± 0.2 | 1.5 ± 0.6d |
| serum albumin (g/dl) | 2.2 ± 0.7 | 2.4 ± 0.5 | 2.2 ± 0.7 |
| proteinuria (g/24 h) | 10.1 ± 6.9 | 6.1 ± 2.3 | 11.1 ± 7.3c |
| 8.4 (5.7–12.7) | 5.5 (4.8–6.3) | 9.5 (6.2–13.3) |
Data are no. (%), mean ± SD, or mean ± SD and median (interquartile range).
a
P < 0.05, versus patients with remission.
b
P < 0.01, versus patients with remission.
c
P < 0.001, versus patients with remission.
d
P < 0.0001, versus patients with remission.